Contemporary data describing the characteristics, treatment, and outcomes of patients with resected, early-stage, PD-L1+ NSCLC are of interest given recently approved therapies, imminent approvals, and upcoming readouts from ongoing phase III clinical trials. Here, CD274 is linked to non-small cell lung carcinoma.